Sucroferric oxyhydroxide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sucroferric oxyhydroxide" in English language version.

refsWebsite

Global rank English rank

16nih.gov

4^th place

10doi.org

2^nd place

7web.archive.org

1^st place

3semanticscholar.org

11^th place

8^th place

2europa.eu

68^th place

117^th place

1tga.gov.au

3,984^th place

2,622^nd place

1hres.ca

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1fda.gov

447^th place

338^th place

doi.org

Chong E, Kalia V, Willsie S, Winkle P (December 2014). "Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects". Journal of Nephrology. 27 (6): 659–66. doi:10.1007/s40620-014-0080-1. PMC 4242982. PMID 24699894.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. (July 2013). "Chronic kidney disease: global dimension and perspectives". Lancet. 382 (9888): 260–72. doi:10.1016/S0140-6736(13)60687-X. PMID 23727169. S2CID 5508863.
Hutchison AJ, Smith CP, Brenchley PE (September 2011). "Pharmacology, efficacy and safety of oral phosphate binders". Nature Reviews. Nephrology. 7 (10): 578–89. doi:10.1038/nrneph.2011.112. PMID 21894188. S2CID 19833271.
Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. (February 2009). "Phosphorus binders and survival on hemodialysis". Journal of the American Society of Nephrology. 20 (2): 388–96. doi:10.1681/ASN.2008060609. PMC 2637053. PMID 19092121.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (August 2009). "KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)". Kidney International Supplements. 76 (113): S1-130. doi:10.1038/ki.2009.188. PMID 19644521.
Wilhelm M, Gaillard S, Rakov V, Funk F (April 2014). "The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro". Clinical Nephrology. 81 (4): 251–8. doi:10.5414/cn108119. PMID 24656315.
Lanz M, Baldischweiler J, Kriwet B, Schill J, Stafford J, Imanidis G (December 2014). "Chewability testing in the development of a chewable tablet for hyperphosphatemia". Drug Development and Industrial Pharmacy. 40 (12): 1623–31. doi:10.3109/03639045.2013.838583. PMID 24010939. S2CID 21386803.
Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, et al. (September 2014). "A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients". Kidney International. 86 (3): 638–47. doi:10.1038/ki.2014.58. PMC 4150998. PMID 24646861.
Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, et al. (June 2015). "Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients". Nephrology, Dialysis, Transplantation. 30 (6): 1037–46. doi:10.1093/ndt/gfv006. PMC 4438742. PMID 25691681.
Kalantar-Zadeh K, Parameswaran V, Ficociello LH, Anderson L, Ofsthun NJ, Kwoh C, et al. (2018). "Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide". American Journal of Nephrology. 47 (3): 153–161. doi:10.1159/000487856. PMC 5906196. PMID 29514139.

europa.eu

ema.europa.eu

"Velphoro EPAR". European Medicines Agency (EMA). 13 October 2014. Archived from the original on 1 July 2020. Retrieved 30 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Velphoro Product Information" (PDF). European Medicines Agency (EMA). Archived (PDF) from the original on 29 August 2021. Retrieved 24 October 2014.

fda.gov

accessdata.fda.gov

"Velphoro (sucroferric oxyhydroxide) Chewable Tablet NDA #205109". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 29 March 2021. Retrieved 30 June 2020.

hres.ca

hpr-rps.hres.ca

"Regulatory Decision Summary for Velphoro". 23 October 2014. Archived from the original on 5 January 2023. Retrieved 11 April 2023.

medicines.org.uk

"Velphoro 500 mg chewable tablets - Summary of Product Characteristics (SmPC)". (emc). 9 April 2019. Archived from the original on 2 July 2020. Retrieved 1 June 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Chong E, Kalia V, Willsie S, Winkle P (December 2014). "Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects". Journal of Nephrology. 27 (6): 659–66. doi:10.1007/s40620-014-0080-1. PMC 4242982. PMID 24699894.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. (July 2013). "Chronic kidney disease: global dimension and perspectives". Lancet. 382 (9888): 260–72. doi:10.1016/S0140-6736(13)60687-X. PMID 23727169. S2CID 5508863.
Hutchison AJ, Smith CP, Brenchley PE (September 2011). "Pharmacology, efficacy and safety of oral phosphate binders". Nature Reviews. Nephrology. 7 (10): 578–89. doi:10.1038/nrneph.2011.112. PMID 21894188. S2CID 19833271.
Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. (February 2009). "Phosphorus binders and survival on hemodialysis". Journal of the American Society of Nephrology. 20 (2): 388–96. doi:10.1681/ASN.2008060609. PMC 2637053. PMID 19092121.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (August 2009). "KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)". Kidney International Supplements. 76 (113): S1-130. doi:10.1038/ki.2009.188. PMID 19644521.
Wilhelm M, Gaillard S, Rakov V, Funk F (April 2014). "The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro". Clinical Nephrology. 81 (4): 251–8. doi:10.5414/cn108119. PMID 24656315.
Lanz M, Baldischweiler J, Kriwet B, Schill J, Stafford J, Imanidis G (December 2014). "Chewability testing in the development of a chewable tablet for hyperphosphatemia". Drug Development and Industrial Pharmacy. 40 (12): 1623–31. doi:10.3109/03639045.2013.838583. PMID 24010939. S2CID 21386803.
Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, et al. (September 2014). "A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients". Kidney International. 86 (3): 638–47. doi:10.1038/ki.2014.58. PMC 4150998. PMID 24646861.
Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, et al. (June 2015). "Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients". Nephrology, Dialysis, Transplantation. 30 (6): 1037–46. doi:10.1093/ndt/gfv006. PMC 4438742. PMID 25691681.
Kalantar-Zadeh K, Parameswaran V, Ficociello LH, Anderson L, Ofsthun NJ, Kwoh C, et al. (2018). "Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide". American Journal of Nephrology. 47 (3): 153–161. doi:10.1159/000487856. PMC 5906196. PMID 29514139.

ncbi.nlm.nih.gov

Chong E, Kalia V, Willsie S, Winkle P (December 2014). "Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects". Journal of Nephrology. 27 (6): 659–66. doi:10.1007/s40620-014-0080-1. PMC 4242982. PMID 24699894.
Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. (February 2009). "Phosphorus binders and survival on hemodialysis". Journal of the American Society of Nephrology. 20 (2): 388–96. doi:10.1681/ASN.2008060609. PMC 2637053. PMID 19092121.
Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, et al. (September 2014). "A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients". Kidney International. 86 (3): 638–47. doi:10.1038/ki.2014.58. PMC 4150998. PMID 24646861.
Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, et al. (June 2015). "Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients". Nephrology, Dialysis, Transplantation. 30 (6): 1037–46. doi:10.1093/ndt/gfv006. PMC 4438742. PMID 25691681.
Kalantar-Zadeh K, Parameswaran V, Ficociello LH, Anderson L, Ofsthun NJ, Kwoh C, et al. (2018). "Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide". American Journal of Nephrology. 47 (3): 153–161. doi:10.1159/000487856. PMC 5906196. PMID 29514139.

dailymed.nlm.nih.gov

"Velphoro- sucroferric oxyhydroxide tablet, chewable". DailyMed. 23 April 2020. Archived from the original on 1 July 2020. Retrieved 1 June 2020.

semanticscholar.org

api.semanticscholar.org

Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. (July 2013). "Chronic kidney disease: global dimension and perspectives". Lancet. 382 (9888): 260–72. doi:10.1016/S0140-6736(13)60687-X. PMID 23727169. S2CID 5508863.
Hutchison AJ, Smith CP, Brenchley PE (September 2011). "Pharmacology, efficacy and safety of oral phosphate binders". Nature Reviews. Nephrology. 7 (10): 578–89. doi:10.1038/nrneph.2011.112. PMID 21894188. S2CID 19833271.
Lanz M, Baldischweiler J, Kriwet B, Schill J, Stafford J, Imanidis G (December 2014). "Chewability testing in the development of a chewable tablet for hyperphosphatemia". Drug Development and Industrial Pharmacy. 40 (12): 1623–31. doi:10.3109/03639045.2013.838583. PMID 24010939. S2CID 21386803.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.

web.archive.org

"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
"Regulatory Decision Summary for Velphoro". 23 October 2014. Archived from the original on 5 January 2023. Retrieved 11 April 2023.
"Velphoro 500 mg chewable tablets - Summary of Product Characteristics (SmPC)". (emc). 9 April 2019. Archived from the original on 2 July 2020. Retrieved 1 June 2020.
"Velphoro- sucroferric oxyhydroxide tablet, chewable". DailyMed. 23 April 2020. Archived from the original on 1 July 2020. Retrieved 1 June 2020.
"Velphoro EPAR". European Medicines Agency (EMA). 13 October 2014. Archived from the original on 1 July 2020. Retrieved 30 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Velphoro Product Information" (PDF). European Medicines Agency (EMA). Archived (PDF) from the original on 29 August 2021. Retrieved 24 October 2014.
"Velphoro (sucroferric oxyhydroxide) Chewable Tablet NDA #205109". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 29 March 2021. Retrieved 30 June 2020.